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Review

The emergence of COVID-19 associated mucormycosis:
a review of cases from 18 countries
Martin Hoenigl*, Danila Seidel*, Agostinho Carvalho, Shivaprakash M Rudramurthy, Amir Arastehfar, Jean-Pierre Gangneux, Nosheen Nasir,
Alexandro Bonifaz, Javier Araiza, Nikolai Klimko, Alexandra Serris, Katrien Lagrou, Jacques F Meis, Oliver A Cornely, John R Perfect, P Lewis White,
Arunaloke Chakrabarti, on behalf of ECMM and ISHAM collaborators†

Reports of COVID-19-associated mucormycosis have been increasing in frequency since early 2021, particularly
among patients with uncontrolled diabetes. Patients with diabetes and hyperglycaemia often have an inflammatory
state that could be potentiated by the activation of antiviral immunity to SARS-CoV2, which might favour secondary
infections. In this Review, we analysed 80 published and unpublished cases of COVID-19-associated mucormycosis.
Uncontrolled diabetes, as well as systemic corticosteroid treatment, were present in most patients with COVID-19associated mucormycosis, and rhino-orbital cerebral mucormycosis was the most frequent disease. Mortality was
high at 49%, which was particularly due to patients with pulmonary or disseminated mucormycosis or cerebral
involvement. Furthermore, a substantial proportion of patients who survived had life-changing morbidities (eg, loss
of vision in 46% of survivors). Our Review indicates that COVID-19-associated mucormycosis is associated with high
morbidity and mortality. Diagnosis of pulmonary mucormycosis is particularly challenging, and might be frequently
missed in India.

Introduction
The world is facing a devastating pandemic, caused by
SARS-CoV-2. Systemic corticosteroid treatment can reduce
mortality in people with the most severe courses
of disease but, together with immunological and other
clinical factors,1 this treatment can also predispose patients
to secondary fungal disease. Although COVID-19associated pulmonary aspergillosis has been the primary
focus in the literature of COVID-19 secondary infections,2,3
other fungal superinfections, including Candida infections,4
rare mould infections (fusariosis),5,6 and COVID-19-asso
ciated mucormycosis7–9 are likely to be under-reported.
The risk factors predisposing patients to mucor
mycosis are uncontrolled diabetes, neutropenia, haema
tological malignancies, organ transplantation, trauma
and burn, and use of immunosuppressants such
as corticosteroids.7,10,11 Furthermore, diabetes is also a
particularly important comorbidity complicating
COVID-19 management.12 Although dexamethasone
has proven beneficial in some groups of patients with
COVID-19 who have been hospitalised, it could increase
the risk of developing invasive mould infections.13
Hyperglycaemia occurs in people with undiagnosed or
uncontrolled diabetes, but it can also be induced by
corticosteroids. Patients with diabetes and hyper
glycaemia often have an inflammatory state that elicits
constant recruitment and local activation of immune
cells, including macrophages and neutrophils, which
secrete proinflammatory cytokines and generate per
sistent inflammation.14 In these patients, the activation
of antiviral immunity to SARS-CoV2 could potentiate
this inflammatory phenotype, which could favour
secondary infections.15
Diagnosis of COVID-19-associated mucormycosis is
challenging as the clinical and radiological features of
pulmonary and disseminated mucormycosis are nonspecific and could overlap with findings thought to be

associated with COVID-19, which results in missed or
late diagnoses.7 Detailed guidance on how to diagnose
mucormycosis7 and when to suspect COVID-19-asso
ciated mucormycosis in patients have been published.9
COVID-19-associated mucormycosis can also be
mistaken for other angioinvasive fungal infections,
particularly with COVID-19-associated pulmonary asper
gi
llosis being the predominant mould disease in
COVID-19-associated acute respiratory distress syn
drome. The reversed halo sign, predominantly in the
peripheral locations of the lung, has been considered to
be suggestive of pulmonary mucormycosis in patients
with immunodeficiency and useful for the initiation of
pre-emptive antifungal therapy;16 however, in patients
with COVID-19, it is less specific as it has also been
described as one of the potential radiological features of
COVID-19.17 Although cavitary lung lesions might be
more specific for mould disease in COVID-19 than the
reversed halo sign, these lesions are frequently observed
in both COVID-19-associated pulmonary aspergi
llosis
and pulmonary COVID-19-associated mucormycosis.2 In
the absence of serum antigenic biomarkers and because
the availability of PCR testing is low, particularly in lowincome and middle-income countries, COVID-19associated mucormycosis diagnosis is also challenging,
with conventional culture and histopathological demons
tration of Mucorales being the mainstay of diagnosis,
albeit with low sensitivity.
Although case reports on COVID-19-associated
mucormycosis continue to emerge, there are still too
few reviews and analyses of large case series that
compare the disease in different areas of the world.18
The objective of this Review was to describe the
epidemiology, risk factors, treatment, and outcome of
COVID-19-associated mucormycosis by analysing pub
lished and unpublished cases of COVID-19-associated
mucormycosis.
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Figure 1: Global distribution of 80 COVID-19-associated mucormycosis cases
Cases were identified from the literature8,21–45 and through experts within the European Confederation of Medical
Mycology, International Society for Human and Animal Mycology, and FungiScope networks.
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Methods

Search strategy and selection criteria
The analysis was initiated by leadership of the European
Confederation of Medical Mycology and International
Society of Human and Animal Mycoses.
We searched PubMed using the search terms:
“(zygomyco* OR mucormycos* OR Mucorales) AND
(COVID-19 OR corona OR SARS-CoV-2 OR pandemic)”
for articles published between Oct 1, 2019 and April 12, 2021.
We also searched the reference lists of all relevant
publications for additional case reports. Information
on epidemiology (age at diagnosis, sex, and country),
underlying conditions, COVID-19 on admission or
previously, intensive care unit procedures, corticosteroid
use, diagnosis of mucormycosis (radiological findings and
mycological evidence), sites of infection (rhinoorbital, pulmonary, and CNS involvement), coinfections,
time between COVID-19 and mucormycosis, clinical
management (systemic antifungal therapy and surgical
procedures), and outcome (overall response, survival,
causes of death [where applicable], and follow-up times)
were extracted from the literature by DS or PLW and
verified in a second review of the articles by the other
reviewer. Reports of new cases were provided via secure
data transfer or through documentation in the FungiScope
registry (a global emerging fungal infection registry).
Cases were reviewed by the FungiScope team and
questions were resolved with the respective contributor.
We identified patients with mucormycosis during or
within 12 weeks after diagnosis of SARS-CoV-2 infection
from the literature and through a global reach-out via
email and social media within FungiScope, European
Confederation of Medical Mycology, and International
Society for Human and Animal Mycology networks during
March and April, 2020.
Cases were classified according to the updated
criteria of the European Organisation for Research and
Treatment of Cancer and the Mycoses Study Group.19
However, the European Organisation for Research and

Treatment of Cancer and Mycoses Study Group have
stated that those criteria are only applicable to patients
with cancer, transplant recipients, and other patients
who are severely immunocompromised, and are not
suitable for patients in intensive care units (ICUs).20
Therefore, criteria for probable disease were modified to
include COVID-19 as host factor and a positive PCR test
for Mucorales as mycological evidence, but criteria for
proven disease remained unchanged.
All probable or proven cases reported or published up
until April 12, 2021, were included in the analysis. Statistical
analyses were done with SPSS 25. We estimated survival
probability using the Kaplan-Meier method. Hazard ratios
and 95% CIs were calculated using the univariate Cox
regression model. Patients were grouped according to the
site of infection—namely, rhino-orbital cerebral mucor
mycosis with CNS involvement, rhino-orbital cerebral
mucormycosis without proof of CNS involvement, and
others (eg, pulmonary, gastrointestinal, and disseminated
mucormycosis)—and survival was compared using the
log-rank test. The Fisher’s exact test was used to compare
demographic characteristics, clinical factors, and out
comes. For all tests, p values of less than or equal to 0·05
defined statistical significance.

Results

Case descriptions
We identified 80 cases of COVID-19-associated mucor
mycosis (63 [79%] proven and 17 [21%] probable),
including 29 (36%) unpublished cases. Cases were
reported from 18 countries, the majority from India (42,
ten of which were unpublished), the USA (eight),
Pakistan (five unpublished from a single centre),
France (four, three of which were unpublished from
two centres), Iran (four, one of which was unpublished),
and Mexico (four, three of which were unpublished from
a single centre), Russia (two unpublished from
two centres; figure 1). Single cases were reported from
Austria, Bangladesh (unpublished), Brazil, Chile, Czech
Republic (unpublished), Germany (unpublished), Italy,
Kuwait (unpublished), Lebanon (unpublished), Turkey,
and the UK.
Prevalence of mucormycosis among people with
COVID-19 who had been admitted to an ICU was
reported from four centres (in France, Germany, Mexico,
and Turkey) and ranged between 0·3% and 0·8%.

Demographics, underlying diseases, and COVID-19
treatments
The majority of patients were male (62 [78%] of 80) and
the median age was 55 years (range 10–86). The table
provides a summary of clinical characteristics and
out
comes of COVID-19-associated mucormycosis in
80 patients and separates data of patients with rhinoorbital cerebral disease from data of those with
pulmonary disease. At the time of COVID-19-associated
mucormycosis diagnosis, 74 (93%) patients were

www.thelancet.com/microbe Published online January 25, 2022 https://doi.org/10.1016/S2666-5247(21)00237-8

Review

COVID-19-associated mucormycosis (n=80)*

Rhino-orbital cerebral disease (n=59)

Pulmonary disease† (n=20)

Median age (range), years

55 (10–86)

54 (10–79)

57 (22–86)

Male-to-female-patient ratio

62:18 (78%:23%)

43:16 (73%:27%)

18:2 (90%:10%)

Country of case origin

India (42 [53%]), USA (8 [10%]), Pakistan (5 [6%]), France
(4 [5%]), Mexico (4 [5%]), Iran (4 [5%]), Russia (2 [3%]),
Austria (1 [1%]), Bangladesh (1 [1%]), Brazil (1 [1%]),
Chile (1 [1%]), Czech Republic (1 [1%]), Germany (1 [1%]),
Italy (1 [1%]), Kuwait (1 [1%]), Lebanon (1 [1%]),
Turkey (1 [1%]), UK (1 [1%])

India (41 [69%]), USA (4 [7%]), Pakistan (1 [2%]),
France (2 [3%]), Mexico (3 [5%]), Iran (4 [7%]),
Russia (2 [3%]), Bangladesh (1 [2%]),
Turkey (1 [2%])

India (1 [5%]), USA (4 [20%]), Pakistan
(4 [20%]), France (2 [10%]), Mexico (1 [5%]),
Austria (1 [5%]), Chile (1 [5%]),
Czech Republic (1 [5%]), Germany (1 [5%]),
Italy (1 [5%]), Kuwait (1 [5%]), Lebanon
(1 [5%]), UK (1 [5%])

Underlying conditions

Diabetes (66 [83%], 55 [83%] of which had uncontrolled
diabetes‡), haematological malignancy (5 [6%]§),
lymphopenia (2 [3%]), hypertension (1 [1%]), chronic kidney
disease (1 [1%]), severe obesity (1[1%]), no known risk factor
(4 [5%])

Diabetes (55 [93%], 48 [87%] of which had
uncontrolled diabetes), haematological
malignancy (1 [2%]), hypertension (1 [2%]),
no known risk factor (2 [3%])

Diabetes (11 [55%], 7 [64%] of which had
uncontrolled diabetes), haematological
malignancy (4 [20%]), lymphopenia
(1 [5%]), chronic kidney disease (1 [5%]),
severe obesity (1 [5%]), no known risk
factor (2 [10%])

Comorbidities¶

Hypertension (14 [18%]), kidney disease (6 [8%]), obesity
(3 [4%]), cardiac disease (5 [6%]), asthma (2 [3%]),
hyperlipidaemia (2 [3%])

Hypertension (7 [12%]), kidney disease (4 [7%]),
obesity (1 [2%]), cardiac disease (2 [3%]),
asthma (2 [3%]), hyperlipidaemia (2 [3%])

Hypertension (6 [30%]), kidney disease
(2 [10%]), cardiac disease (3 [15%]),
hypothyroidism (1 [5%]), pancreatitis
(1 [5%]), obesity (1 [5%])

COVID-19 diagnosis

On admission (58 [68%]), previous (10 [13%]), during
admission (1 [1%]), unknown (14 [18%])

On admission (37 [63%]), previous (9 [15%]),
unknown (13 [22%])

On admission (17 [85%]), previous (1 [5%]),
during admission (1 [5%]), unknown
(1 [5%])

COVID-19 severity

Severe or critical (36 [45%]), mild or moderate (36 [45%]),
asymptomatic (2 [3%]), unknown (6 [8%])

Severe or critical (19 [32%]), mild or moderate
(33 [56%]), asymptomatic (2 [3%]), unknown
(5 [8%])

Severe or critical (16 [80%]), mild or
moderate (4 [20%])

Intensive care unit admission

Yes (38 [48%]), no (34 [43%]), unknown (8 [10%])

Yes (19 [32%]), no (33 [56%]), unknown (7 [12%]) Yes (18 [90%]), no (1 [5%]), unknown
(1 [5%])

Corticosteroids administered

Yes (63 [79%])||, no (14 [18%]), unknown (3 [4%])

Yes (47 [80%]), no (10 [17%]), unknown (2 [3%])

Yes (15 [75%]), no (4 [20%]), unknown
(1 [5%])

Causative Mucorales spp

Rhizopus spp (16 [20%]), Mucor spp (6 [8%])**,
R arrhizus (11 [14%]), R microsporus (7 [9%]), Lichtheimia spp
(1 [1%]), Rhizomucor pusillus (1 [1%]), not specified
(39 [49%])

Rhizopus spp (10 [17%]), Mucor spp (6 [10%])**,
R arrhizus (8 [14%]), Lichtheimia spp (1 [2%]),
R microsporus (1 [2%]), not specified (34 [58%])

Rhizopus spp (6 [30%]), R microsporus
(6 [30%]), R arrhizus (3 [15%]),
R pusillus (1 [5%]), not specified (4 [20%])

Antifungal therapy

Liposomal amphotericin B (54 [68%]), conventional
amphotericin B (9 [11%]), unknown amphotericin B
formulation (7 [9%]), amphotericin lipid complex (2 [3%]),
voriconazole (5 [6%]) isavuconazole (5 [6%]), posaconazole
(6 [8%]), caspofungin (2 [3%]), micafungin (1 [1%]),
antifungal combination (ie, drugs simultaneously; 14 [18%]),
none (2 [3%]), unknown (1 [1%])

Liposomal amphotericin B (44 [75%]),
conventional amphotericin B (5 [8%]), unknown
amphotericin B formulation (6 [10%]),
amphotericin lipid complex (2 [3%]), voriconazole
(2 [3%]), isavuconazole (2 [3%]), posaconazole
(6 [10%]), caspofungin (1 [2%]), antifungal
combination (ie, drugs simultaneously; 10 [17%]),
none (1 [2%]), unknown (1 [2%])

Liposomal amphotericin B (10 [50%]),
conventional amphotericin B (4 [20%]),
unknown amphotericin B formulation
(1 [5%]), voriconazole (3 [15%]),
isavuconazole (3 [15%]), caspofungin
(1 [5%]), micafungin (1 [5%]), antifungal
combination (ie, drugs simultaneously;
4 [20%]), none (1 [5%])

Surgical intervention

Yes (45 [56%]), no (29 [36%]), deferred or unknown (6 [8%]) Yes (43 [72%]), no (12 [20%]), deferred or
unknown (4 [7%])

Therapeutic strategy

Systemic antifungals plus surgery (44 [55%]), systemic
antifungals only (32 [40%]), surgery only (1 [1%]),
none (2 [3%]), unknown (1 [1%])

Systemic antifungals plus surgery (42 [71%]),
systemic antifungals only (15 [25%]), surgery only
(1 [2%]), unknown (1 [2%])

Systemic antifungals plus surgery (2 [10%]),
systemic antifungals only (17 [85%]), none
(1 [5%])

Fungal coinfections

Aspergillosis (9 [11%]), none (71 [89%])

Aspergillosis (3 [5%]), none (56 [95%])

Aspergillosis (6 [30%]), none (14 [70%])

Outcome

Survived (37 [46%]), died (39 [49%]), unknown (4 [5%])

Survived (33 [56%]), died (22 [37%]), unknown
(4 [7%])

Survived (4 [20%]), died (16 [80%])

Life-changing morbidities in
survivors

Loss of vision (19 [24%])

Loss of vision (19 [32%])

..

Yes (2 [10%]), no (16 [80%]), deferred or
unknown (2 [10%])

Data are n (%) unless otherwise specified; n is the number of patients and the percentage is the proportion of patients out of the total indicated at the top of the column. *Includes 59 patients with rhino-orbital
cerebral disease, 20 patients with pulmonary disease (three of whom had disseminated pulmonary disease), and one patient with gastrointestinal disease. †Includes 17 patients with pulmonary disease only and
three patients with pulmonary disease and disseminated disease. ‡Well-controlled diabetes was reported in eight (12%) of 66 patients; the diabetes status of patients was unknown in three of 66 patients.
§Two patients had lymphoma, two patients had acute myeloid leukaemia, and one patient had acute lymphoblastic leukaemia. ¶ Numbers are super-additive. || Details available from 40 patients: 28 patients
were given dexamethasone 6 mg for 10 days, and 12 were given methylprednisolone (40–120 mg for 5–28 days after hospital admission).**Rhizopus and Mucor spp was identified in one patient.

Table: Summary of clinical characteristics, treatment, and outcome of 80 cases of patients with COVID-19-associated mucormycosis

hospitalised with ongoing COVID-19 infection, and
six (8%) patients had COVID-19 infection before
hospitalisation for mucormycosis-associated symptoms,
four of whom were hospitalised for treatment of
COVID-19 1–3 months before mucormycosis diagnosis.

Most patients (76 [95%] of 80) had additional risk
factors. Diabetes was the most prevalent condition overall
(66 [83%] of 80), with type 2 diabetes being more common
than type 1 diabetes (59 [89%] of 66 patients with diabetes
had type 2 and 6 [9%] had type 1). Most of the 66 patients
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with diabetes had uncontrolled or poorly controlled
diabetes (reported in 55 [83%] of 66), as characterised by
diabetic ketoacidosis (27 [49%] of 55), hyper
glycaemia
(23 [42%] of 55), elevated HbA1c levels (available in
23 [77%] of 30 patients in whom HbA1c levels were
available; median 11·0% [range 7·2–15·5%] and median
14·9 mmol/L [8·9–22·1 mmol/L]), or end-stage renal
disease (6 [9%] of 66). Specifically, diabetes was a more
predominant risk factor in patients from India than in
patients from other countries (40 [95%] of 42 patients in
India vs 26 [68%] of 38 from other countries, p=0·0024).
Hypertension was the second most common underlying
condition, identified in 15 (19%) of 80 patients, followed
by chronic kidney diseases (five [6%]), and haematological
malignancies (five [6%]). No apparent risk factor, aside
from COVID-19, was noted in only four (5%) of
80 patients.
Treatment with systemic corticosteroids was reported
in 63 (79%) of 80 cases, and 51 (81%) of 63 patients given
systemic corticosteroids started treatment before the
diagnosis of mucormycosis. Tocilizumab was given to
six patients in addition to corticosteroids.

Clinical presentation and diagnosis
Patients with mucormycosis most commonly had rhinoorbital cerebral infection (59 [74%] of 80), with extension
into the CNS confirmed in 22 (37%) of 59 patients. Rhinoorbital cerebral infection was particularly common in
patients from India, where 41 (98%) of 42 patients had
rhino-orbital cerebral infection (proof of cerebral
involvement in 11 [27%] of 41 patients). Pulmonary disease
was reported in 20 (25%) patients, three of whom had
disseminated mucormycosis with sinus (one patient) or
CNS (two patients) involvement, and one patient had
gastrointestinal mucormycosis. Among patients with
pulmonary disease, 18 (90%) of 20 patients were admitted
to the ICU, mostly with severe or critical COVID-19
(15 [83%] of 18). Rhino-orbital cerebral mucormycosis
was mostly seen in patients with diabetes (55 [93%] of
59 patients with rhino-orbital cerebral disease had
diabetes, only four of whom had well-controlled blood
sugar concentrations), whereas patients with other
clinical manifestations of mucor
mycosis (20 with
pulmonary and one with gastrointestinal COVID-19associated mucor
mycosis) were less likely to have
diabetes (11 [52%] of 21, four of whom had well-controlled
blood sugar concentrations) than were those with rhinoorbital cerebral mucormycosis (p<0·0001). Four of
the five patients with haematological malignancy had
pulmonary mucormycosis during management of severe
COVID-19 in the ICU and one patient had rhino-orbital
cerebral infection 3 months after diagnosis of
severe COVID-19. In the patients with pulmonary,
gastrointestinal, or disseminated mucormycosis, the
majority (17 [81%] of 21) had severe or critical COVID-19,
whereas in the patients with rhino-orbital cerebral
infection, COVID-19 was mainly mild or moderate (in
4

35 [59%] of 59). Mucormycosis was diagnosed at a median
of 10 days (range 0–90 days) after diagnosis of COVID-19;
19 patients hospitalised with COVID-19 had clinical signs
of mucormycosis at the time of admission (18 had rhino–
orbital cerebral mucormycosis and 16 of these 18
had poorly controlled diabetes, and one patient with
haematological malignancy presented with pulmonary
infection). In the 61 patients who did not show signs of
mucormycosis at the time of hospital admission,
diagnosis was made at a median of 14·5 days (1–90 days)
after admission. In the 55 patients with uncontrolled
diabetes, COVID-19-associated mucor
mycosis was
diagnosed in a median of 3·5 days (0–50 days) after
COVID-19 (48 [87%] of 55 had rhino-orbital cerebral
infection), versus a median of 20 days (0–60 days) in the
11 patients with controlled diabetes (7 [64%] of 11 had
rhino-orbital cerebral infection). 25 (31%) patients
required advanced critical care for at least 1 day before the
onset of mucormycosis. In these patients, mucormycosis
was diagnosed a median of 8·0 days (1–35 days) after
admission to the ICU.
Proven diagnosis of mucormycosis, based on histology
or culture of tissue or other samples from sterile sites, was
obtained in 63 (79%) patients (five of those were obtained
post mortem), with radiological abnormalities (eg,
sinusitis, necrosis in patients with rhino-orbital cerebral
mucormycosis, and nodules or cavities in patients with
pulmonary disease) described in 40 (64%) of 63 patients.
Probable pulmonary mucormycosis was confirmed by
radiological findings and a positive culture or PCR from
respiratory samples in 14 (82%) of 17 patients with rhinoorbital cerebral disease and by positive culture from swab
or scraping samples in the other three (18%) patients with
rhino-orbital cerebral disease.
Identification to the genus level was described in
25 [42%] of 59 patients with rhino-orbital cerebral infection
and in 16 [76%] of 21 with pulmonary, gastrointestinal, or
disseminated disease, and 19 of these infections were
described to the species level. Rhizopus spp were the most
common species identified, identified in 19 (32%) of
59 patients with rhino-orbital cerebral infection and 15
(71%) of 21 patients with pulmonary, gastrointestinal, or
disseminated disease. Mucor spp were identified only in
patients with rhino-orbital cerebral disease (six of
59 patients). Nine patients had mixed infection with
Aspergillus spp, six of whom had pulmonary disease, and
two of the three patients with rhino-orbital cerebral disease
had proven cerebral involvement.

Treatment and outcome of COVID-19-associated
mucormycosis
Systemic antifungal agents targeted against mucor
mycosis were used in all but three patients. Amphotericin
B formulations were used in the vast majority of patients
(71 [89%] of 80), and posaconazole was used in addition
to amphotericin B in six patients with rhino-orbital
cerebral mucormycosis. Isavuconazole was used in five
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rhino-orbital cerebral diseases without proven CNS
involvement [p=0·11], and compared with other forms of
the disease [p=0·071]).

Discussion
In this Review, we describe 80 cases of COVID-19associated mucormycosis, with a predominance (42 of 80)
of cases from India. There were three major findings:
uncontrolled diabetes and systemic corticosteroid
treatment were present in large proportions of patients;
rhino-orbital cerebral mucormycosis was the most
frequent presentation of disease (74%) and was present in
41 of 42 patients from India, whereas pulmonary disease
almost exclusively occurred in the ICU setting and was
present in 50% of patients reported from outside India;
and amphotericin B formulations and surgery were the
predominant treatment strategies, but mortality was
high at 49%, mostly because of the high mortality of
patients with pulmonary or disseminated mucormycosis
and those with cerebral involvement. Furthermore, a
substantial proportion of surviving patients had
life-changing morbidities (eg, loss of vision in
46% of survivors).
Uncontrolled diabetes, and specifically ketoacidosis (in
27 [49%] of 55 patients) and systemic corticosteroid
treatment (in 79% of patients), was present in a large
proportion of our COVID-19-associated mucormycosis
cohort, suggesting that patients with diabetes and
COVID-19 receiving corticosteroids might be particularly
susceptible to the development of COVID-19-associated
mucormycosis. In particular, diabetes was almost
ubiquitous in patients from India (present in 95% of
ROCM without CNS involvement (n=17, 5 deaths)
ROCM with CNS involvement (n=13, 8 deaths)
Other (eg, pulmonary, gastrointestinal, and disseminated mucormycosis; n=21, 17 deaths)
100
ROCM without vs with CNS log-rank p=0·11 (HR 2·44 [95% Cl 0·79–7·50], p=0·12)
ROCM with CNS vs other log-rank p=0·071 (HR 2·19 [95% Cl 0·91–5·31], p=0·082)
ROCM without CNS vs other log-rank p=0·0019 (HR 4·21 [95% Cl 1·54–11·48], p=0·0050)
80
Probability of survival (%)

patients, either in combination with amphotericin B
(two patients), as salvage therapy (two patients), or as
monotherapy (one patient). In addition, 45 (58%) patients
underwent surgical resection (43 [96%] of 45 had rhinoorbital cerebral mucormycosis, of whom 16 had orbital
exenteration).
All-cause mortality occurred in 39 (49%) of 80 patients.
Mortality was reported in 22 (37%) of 59 patients who
had rhino-orbital cerebral mucormycosis and in 17 (81%)
of 21 patients who had pulmonary, gastrointestinal,
or disseminated mucormycosis (p<0·0008). Mortality
in patients with rhino-orbital cerebral disease with
confirmed CNS involvement was higher (13 [59%] of
22 patients) than in those without signs of progression to
the CNS (nine [24%] of 37 patients; p=0·012). Among
survivors, loss of vision was reported in 19 (46%) of
41 patients (all with rhino-orbital cerebral mucormycosis).
Surgery was associated with improved outcomes in
rhino-orbital cerebral mucormycosis in patients without
proven CNS involvement, in whom mortality was higher
in those who received systemic antifungals alone
(five [63%] of eight) than in those who also had surgery
(four [14%] of 29, of whom one had only surgery; p=0·012).
Surgery did not significantly affect survival for patients
with rhino-orbital cerebral mucormycosis who had proven
CNS involvement (mortality in five [71%] of seven of
patients who were given systemic antifungals alone vs
eight [57%] of 14 who also had surgery; p=0·66).
14 (18%) patients required ICU treatment after the
diagnosis of mucormycosis was made, 11 of whom were
admitted with COVID-19 and clinical signs of rhinoorbital cerebral mucormycosis. Patients with severe or
critical COVID-19 were more frequently treated in
the ICU (30 [86%] of 36) than were patients with mild or
moderate COVID-19 (seven [26%] of 37; p<0·0001).
Overall, admission to the ICU was associated with
worse outcomes, with overall mortality in 27 (71%) of
38 patients treated in the ICU versus 11 (32%) of
34 patients not treated in the ICU (p<0·0019).
For patients with a fatal outcome, median survival time
from the day of diagnosis of mucormycosis was 106 days
(95% CI 9·4–202·3) for patients with rhino-orbital
cerebral disease versus 9 days (2·4–15·6) for patients
with pulmonary mucormycosis. Kaplan-Meier survival
analysis showed a higher survival probability in patients
with rhino-orbital cerebral disease without proven CNS
infection than in those with other forms of the disease
(17 with pulmonary disease, three with disseminated
disease [including pulmonary mucormycosis], and one
with gastrointestinal disease; log-rank p=0·0019; hazard
ratio 4·210 [95% CI 1·54–11·48]; figure 2). Median
survival time for patients with proven CNS involvement
during rhino-orbital cerebral disease was 26 days
(17·4–34·6), and survival over the disease course did not
significantly differ from that in patients without proven
CNS involvement and those with other forms of COVID19-associated mucormycosis disease (compared with
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Figure 2: Survival estimation of COVID-19-associated mucormycosis cases
Kaplan-Meier survival estimation for patients with rhino-orbital cerebral disease without CNS involvement,
rhino-orbital cerebral mucormycosis with CNS involvement, and other forms of mucormycosis (eg, pulmonary,
gastrointestinal, and disseminated). HR=hazard ratio.
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patients). However, in pulmonary cases, most of which
were reported in patients from Europe and the USA,
diabetes was observed in 55% of patients with COVID-19associated mucormycosis, which was higher than in a
previous multinational cohort of patients in ICUs with
COVID-19 acute respiratory failure without COVID-19associated mucormycosis (27% of patients had diabetes).3
Although diabetes was frequently observed as an
underlying disease, poor glycaemic control might be a
specific predictor of rhino-orbital cerebral COVID-19associated mucormycosis. Patients with uncontrolled
diabetes developed mucormycosis (87% had rhino-orbital
cerebral) a median of 2–3 weeks earlier after diagnosis of
COVID-19 than patients with well-controlled diabetes, in
whom 64% had COVID-19-associated mucormycosis that
was rhino–orbital cerebral. The most probable mechanism
behind this observation is the hyperglycaemia-induced
inflammatory state that might be potentiated once antiviral
immunity to SARS-CoV-2 activates. Moreover, Mucorales
induce an augmented secretion of proinflammatory
cytokines by immune cells.46 Therefore, even in the absence
of immunosuppressive therapies, several divergent
inflammatory pathways in patients with COVID-19 might
act together to establish an inflammatory environment
that is highly permissive to the development of COVID-19associated mucormycosis, potentiating the expression of
specific virulence factors and associated host damages. In
a large randomised controlled trial in patients who were
critically ill with COVID-19, treatment with IL-6 receptor
antagonists improved outcomes, including survival.47
However, it is not known whether this therapeutic strategy
of dampening an important cytokine in antifungal
immunity could predispose patients to COVID-19associated mucormycosis.
78% of COVID-19-associated mucormycosis cases
reported in this Review occurred in male patients.
Whether this gender imbalance might be the result of
differing susceptibility—confirming what was recently
observed in a diabetic ketoacidosis mouse model (in
which female mice were more resistant to Mucorales
infection than male mice)48—needs to be investigated in
future studies.
The invasion of host cells during mucormycosis is
elicited by the spore coat protein homologue, CotH3,
which has been shown to mediate the interaction between
spores and GRP78 on nasal epithelial cells to promote
invasion and damage.49 GRP78 can also be upregulated in
patients with COVID-19, and experimental studies have
shown that GRP78 can form a complex with the spike
protein and ACE2 to act as a host auxiliary factor for
SARS-CoV2 entry and infection.50 The relevance of these
mechanisms to human disease is supported by the
induction of GRP78 by host factors characteristic of
diabetic ketoacidosis, namely high glucose concentration,
high iron concentration, and ketone bodies. Additionally,
Mucorales produce the toxin mucoricin, which displays
structural and functional features of the plant toxin ricin,
6

and is endowed with the ability to induce inflammation,
vascular permeability in vitro, and hypovolaemic shock
and organ necrosis in mouse models of mucormycosis.51
Therefore, vascular endothelial injury, potentiated by
COVID-19-associated inflammation, might also represent
an important susceptibility feature of mucormycosis.
On a cellular level, COVID-19 and its management
might augment development of COVID-19-associated
mucormycosis. First, the ability to restrict intracellular
iron availability and inhibit fungal persistence and growth
is an essential mechanism required to counter infection
with Mucorales.52 With increased free iron concentrations
observed in most patients with COVID-1953 and the
Mucorales species’ need for free iron for their biological
processes, iron availability might represent a crucial
mechanism involved in the pathogenesis of COVID-19associated mucormycosis.54 Serum concentration of free
iron is also increased in people with COVID-19 and
ketoacidosis due to the release of iron from binding
proteins during acidosis.55 In this context, the renal
tropism of SARS-CoV2 might also become relevant to
COVID-19-associated mucormycosis, as patients with
renal failure undergoing deferoxamine chelation have
increased concentrations of circulating free iron (since
deferoxamine acts as a siderophore for Mucorales), and
are more likely to develop mucormycosis than are patients
not undergoing deferoxamine chelation.54 Second, the
impairment of neutrophil migration, ingestion, and
phagolysosome fusion caused by corticosteroids (reported
in 79% of patients in this Review) might amplify the risk
for mucormycosis. Third, the dysbiosis exerted by the
intensive use of antibiotic treatment, along with the
severe injuries of the epithelium, provide a permissive
environment for developing invasive fungal infections,1,4
including mucormycosis. Fourth, severe lymphocytopenia
and lymphocyte dysfunction might also influence the
development of COVID-19-associated mucormycosis as
the decreased naive T-cell responses in patients with
COVID-19 are aggravated with diabetes;56 Mucoralesspecific T cells are detected in patients with mucormycosis
and display important direct fungicidal activity.57
There might be several explanations for the observed
differences between COVID-19-associated mucormycosis
cases in India, where rhino-orbital cerebral disease
was present in 41 of 42 patients compared with
18 of 38 patients from outside India. First, the distribution
of Mucorales species varies between geographical
regions, with Rhizopus arrhizus being the most common
species in India58 and Cunninghamella spp being the
most common species in Spain.59 Second, there might be
differences in environmental exposure of pathogens, as
ecological studies from India indicate the presence of
many species of Mucorales in the soil and a large number
of spores in indoor environments, such as air
conditioning filters and hospital air, and in outdoor air.60
16 (80%) of 20 patients with pulmonary involvement had
severe or critical COVID-19, and 18 (90%) required
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treatment in an ICU for acute respiratory failure, whereas
only 19 (32%) of 59 patients with rhino-orbital cerebral
mucormycosis had severe COVID-19 and 20 (34%) of
59 patients were admitted to an ICU. This finding might
support the notion that the rhino-orbital cerebral form of
COVID-19-associated mucormycosis occurs more
frequently outside the ICU setting and, possibly, in
patients with less severe COVID-19, than other forms of
COVID-19-associated mucormycosis.
Only 6% of cases were diagnosed at autopsy, highlighting
the challenges of diagnosing mucormycosis and indicating
that the prevalence of COVID-19-associated mucormycosis
might be underestimated, considering the rareness of
autopsies, particularly among patients dying with COVID-19
in high numbers in resource-limited countries.61 Although
bronchoalveolar lavage and biopsy samples can be difficult to
obtain in patients with COVID-19, there is hope for more
specific diagnostic tests. Several studies have shown that
Mucorales PCR on blood samples, and in other matrices
such as bronchoalveolar lavage or tissue specimens, is an
early, sensitive, and specific non-invasive tool for diagnosis
and monitoring of treatment efficacy.62,63 In-house assays
are designed to detect the most relevant Mucorales,
including Mucor spp, Rhizopus spp, Lichtheimia spp, and
Rhizomucor spp.62,63 A Mucorales multiplex real-time PCR
assay (MucorGenius, Pathonostics, Maastricht, Netherlands)
that is easy to use adds Cunninghamella spp to the main
Mucorales and was shown to be effective both in
bronchoalveolar lavage and serum.64,65 Molecular techniques
to detect Mucorales are now considered new pivotal strategies
for the diagnosis of mucormycosis and should be more
broadly used in patients with COVID-19-associated
mucormycosis (PCR results were only reported in one patient
in this Review). Although PCR can provide species-level
identification, a positive culture is required for in-vitro
susceptibility testing. Indeed, a decrease in susceptibility to
lipid-based amphotericin B or isavuconazole has been
reported for some genera; therefore, species-level
identification might be helpful to the clinician.7
The treatment of mucormycosis in patients with
COVID-19 is similar to the treatment of patients with
this invasive mycosis in other risk groups. However,
treatment of mucormycosis in patients with COVID-19
is generally associated with fewer issues regarding
neutropenia management than in patients with
haematological malignancies, for example, but it is more
focused on diabetes and corticosteroid exposure than in
other risk groups. The three pivotal treatment principles
of mucormycosis are control of the underlying disease or
risk factor, surgical debridement of necrotic infected
tissue, and specific antifungal therapy.7 First, it is
important to carefully control glucose intolerance and
rapidly treat any ketoacidosis. The reduction and
elimination of long-term high-dose corticosteroids
should be considered. Second, necrotic tissue resulting
from major invasive mould infection should be carefully
debrided to control the infection. This strategy needs to

be done at the bedside by skilled surgeons in cooperation
with the medical team. A common mistake is to delay
crucial surgical debridement and assume antifungal
agents alone will successfully treat the infection.
In this group of patients with COVID-19-associated
mucormycosis, we did see a positive outcome with
surgery for rhino-orbital disease without proven
CNS disease. Although surgical intervention is often
essential in the successful management of mucormycosis,
specific robust guidelines are difficult to develop that
allow precision and the correct technical outcomes.
Third, the use of antifungal agents is an essential feature
of treatment. Initial antifungal therapy of serious lifethreatening mucormycosis is generally centred around
the most potent and broad-spectrum class of drugs, the
polyenes, including amphotericin B.66 If available, lipid
formulations of amphotericin B treatment are favoured
because they have less nephrotoxicity than other
formulations, especially when given in high daily doses.67
Two extended-spectrum azoles, isavuconazole and
posaconazole, have emerged as viable alternatives to
liposomal amphotericin B in the treatment of
mucormycosis, particularly in patients with impaired
renal function.7,68 However, it is important to recognise
that mucormycosis is caused by various genera and
species, and some of the Mucorales respond poorly to
azoles in vitro. Therefore, lipid amphotericin B
formulations remain the primary treatment, which was
also shown in this Review with 89% of patients receiving
amphotericin B formulations. Following the guidelines,
over half of the patients received additional surgical
debridement. The observed all-cause mortality of 49%,
which was highest for patients with pulmonary or
disseminated mucormycosis and for patients with
cerebral involvement, suggests that the prognosis of
mucormycosis with SARS-CoV-2 is dismal, even with
amphotericin B treatment and surgery. In this Review,
the mortality rate was higher than it was in a large review
of patients with diabetes and mucormycosis (44%).66
The currently available therapeutic interventions are
not sufficient in reducing the high mortality associated
with mucormycosis. Fortunately, genetic studies
have identified new genes and widespread genome
duplications in mucormycetes, allowing researchers to
characterise virulence factors, such as versatility, robust
growth, and multidrug resistance. These new insights
might expose promising targets for future antifungal
therapies.69 Many antifungal agents are less effective for
the treatment of mucormycosis than for the treatment
of aspergillosis. At present, new antifungal drugs in
development have some in-vitro activity against
Mucorales, but robust clinical studies are difficult and
are not likely to be done in the short-term. Treatment of
mucormycosis will generally be empirical for the near
future. Other alternative strategies against mucormy
cosis should be considered in serious cases.70
Current challenges in diagnosis and management of
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Panel: Current challenges in diagnosis and management of COVID-19-associated
mucormycosis
Little awareness of COVID-19-associated mucormycosis71
The countries with a high incidence of diabetes and COVID-19 (eg, Bangladesh, India,
Pakistan, Iran, Mexico, China, Russia, Indonesia, and the USA) should monitor patients
closely for a month after recovery from COVID-19, as most cases of COVID-19-associated
mucormycosis are detected within this time period. COVID-19-induced immune
dysregulation is seen late in the COVID-19 clinical course. Patients can be advised on
discharge from hospital after COVID-19 recovery to look for nasal blockage, increased
nasal discharge, and eye swelling and to seek urgent medical attention if these symptoms
occur. This advice can help in the early diagnosis of cases. Mucormycosis is a rare disease:
the literature contains only case reports without much knowledge of the prevalence of
COVID-19-associated mucormycosis. There is a need for a multicentre epidemiology
study to understand the impact of the disease.
Diagnosis of COVID-19-associated mucormycosis
Diagnosis of pulmonary mucormycosis is a major challenge in patients with COVID-19
due to avoidance of respiratory samples or bronchoscopy. Pulmonary mucormycosis
should be suspected not only in patients in classical risk groups (eg, haematological
malignancy, solid organ transplantation, and autoimmune diseases) but also in other
patient groups, including those with COVID-19. Pulmonary cavities or multiple nodules
on chest CT would suggest that a closer assessment is needed of other characteristic
imaging signs (including bronchoscopy, biopsy, and molecular testing from obtained
respiratory specimens), not to be confused with COVID-19 lesions. Other than rhinoorbital cerebral sites, diagnosis of mucormycosis at other sites is a challenge, potentially
explaining the near absence of pulmonary COVID-19-associated mucormycosis diagnoses
in India. Broader global availability of standardised molecular diagnostics of
mucormycosis in the blood of patients are needed.72
Treatment of COVID-19-associated mucormycosis
Steroids are given indiscriminately in patients who are in hospital with COVID-19.
Simultaneously, close glycaemic control is required in patients with diabetes as uncontrolled
diabetes is the major risk factor for rhino-orbital cerebral mucormycosis. COVID-19 can
damage β cells of the pancreas, resulting in metabolic derangement and eventually
diabetes.73,74 The cost of treating mucormycosis is a serious challenge in low-income and
middle-income countries, and a considerable number of patients cannot afford therapy.
Knowledge of managing mucormycosis is also a challenge among clinicians in low-income
and middle-income countries.75

COVID-19-associated mucormycosis are outlined in the
panel.
Limitations of our study include that not all data were
available for all cases; the absence of a control cohort did
not allow us to draw firm conclusions regarding risk
factors for COVID-19-associated mucormycosis; and
underlying conditions and risk factors might have been
under-reported, particularly at resource-limited centres.

Conclusion
COVID-19-associated mucormycosis can be a serious
complication of severe COVID-19, particularly in patients
with uncontrolled diabetes. The complex relationship
between COVID-19 and mucormycosis is still mostly
unknown. Diagnosis of pulmonary and gastrointestinal
mucormycosis is challenging and might frequently be
missed, particularly in India and other low-income and
8

middle-income countries. Despite its reputation as a
difficult-to-treat mould infection and its high mortality in
patients with COVID-19, particularly those with
pulmonary disease, a careful management plan can be
successful for rhino-orbital cerebral disease if there is
early diagnosis of infection and control of COVID-19.
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